tirzepatide egfr SURPASS-4: slows kidney disease in adults with type 2 diabetes, CV risk Tirzepatide in CKD: FDA, ADA,

The medication is administered via a subcutaneous injection in the upper arm, thigh, or abdominal area

Phase 2 trials studied up to 12 mg weekly, but no approved dosing regimen exists in the UK

A newly published study has intensified scrutiny over GLP-1 receptor agonists like Ozempic, Mounjaro, and Trulicity, linking them to significantly higher rates of gastrointestinal side effects compared to older diabetes medications

Taking three pills per day may also not appeal to everyone

In adolescents and children with type 2 diabetes, this dual activation can reduce appetite-driven overeating while simultaneously improving the body's own insulin function